Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 541

Sort by

Sort Order Select

Journal Articles

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

Cheng Zhang, Jiaping He, Li Liu, Jishi Wang, PhD, Sanbin Wang, Ligen Liu, Lei Gao, Li Gao, Yao Liu, Peiyan Kong, Jia Liu, Yu Han, Yongliang Zhang, Zhe Sun, Xun Ye, Yan He, Lianjun Shen, MD PhD, Wei Cao, Xi Zhang

Blood (2019) 134 (Supplement_1): 1340.

https://doi.org/10.1182/blood-2019-128006

Published: 2019

Journal Articles

A Novel 10-Fluorochrome Multiparameter Flow Cytometry (MFC) Panel for Precise Plasma Cell (PC) and MRD Assessment in Clinical Routine of Multiple Myeloma (MM) Patients and throughout the Disease Course

Veronika Riebl, Sandra M. Woerner, Dagmar Wider, Marie Follo, Stefan J. Mueller, Cornelius Miething, Mihaela Zlei, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 1789.

https://doi.org/10.1182/blood-2019-124680

Published: 2019

Journal Articles

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Wenqun Zhang, MD, Bo Hu, MD, Ling Jing, MD, Jing Yang, MD, Shan Wang, MD, Yang Liu, MD, Juan Du, MD, Yaoliang Ren, MD, Yonghong Zhang, MD

Blood (2019) 134 (Supplement_1): 1945.

https://doi.org/10.1182/blood-2019-125753

Published: 2019

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

Successful Treatment of Refractory Acute Lymphoblastic Leukemia with Tisagenlecleucel in the Setting of Life-Threatening Infection

Keith J August, MDMS, Terrie Flatt, DO,MA, Erin Marie Hall, MD, Doug Myers, MD

Blood (2019) 134 (Supplement_1): 5125.

https://doi.org/10.1182/blood-2019-130880

Published: 2019

Journal Articles

Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia

Lamis K. Eldjerou, MD, Christopher Acker, BS, Damien Howick, MSc, Lee Clough, RN, Miriam Fuchs, MD PhD, Florence Salmon, PhD, Jennifer Willert, MD, Ranjan Tiwari, MSc, Mayo Pujols, MS, Matthew Robson, MD

Blood (2019) 134 (Supplement_1): 5066.

https://doi.org/10.1182/blood-2019-127346

Published: 2019

Journal Articles

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

Hua Zhang, Lei Gao, Li Liu, Jishi Wang, PhD, Sanbin Wang, Li Gao, Cheng Zhang, MD PhD, Yao Liu, Peiyan Kong, Jia Liu, Jiaping He, Yu Han, Hua Shi, Yan He, Xun Ye, Yi Zhao, Wei Cao, Lianjun Shen, Xi Zhang

Blood (2019) 134 (Supplement_1): 3147.

https://doi.org/10.1182/blood-2019-131056

Published: 2019

Journal Articles

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Jeffrey J. Bednarski, MD PhD, Clare Zimmerman, MD, Amanda F Cashen, MD, Sweta Desai, Mark Foster, Tim Schappe, BS, Ethan McClain, Michelle Becker-Hapak, BS, Melissa M Berrien-Elliott, PhD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 3307.

https://doi.org/10.1182/blood-2019-126982

Published: 2019

Journal Articles

Influence of CD27 - CD28 - T-Cells on the Therapeutic Outcome in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma after CART-Infusion

Nina Worel, MD, Katharina Pfistershammer, Winfried Pickl, Marion Heinz, RN, MPhil, Martina Schlager, Beate Pribitzer, Andreas Tanzmann, MD, Ulrich Jaeger, MD, Georg Hopfinger

Blood (2019) 134 (Supplement_1): 1935.

https://doi.org/10.1182/blood-2019-126191

Published: 2019

Journal Articles

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

Bryan Hambley, MD, Eric Gehrie, Jonathan Webster, MD, Margaret M. Showel, MD, Lukasz P. Gondek, MD PhD, William Brian Dalton, MD PhD, Gabrielle T. Prince, MD, Douglas E Gladstone, MD, Ivana Gojo, MD, Gabriel Ghiaur, MD PhD, Keith W. Pratz, MD, B. Douglas Smith, MD, Amy E. DeZern, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 3841.

https://doi.org/10.1182/blood-2019-123229

Published: 2019

Journal Articles

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 825.

https://doi.org/10.1182/blood-2019-121751

Published: 2019

Journal Articles

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Changju Qu, PhD, Jia Yin, Liqing Kang, Zheng Li, Haiping Dai, Xiaming Zhu, Lei Yu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3822.

https://doi.org/10.1182/blood-2019-128013

Published: 2019

Journal Articles

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Aspasia Stamatoullas, MD, Herv Ghesquieres, Lauriane Clement filliatre, MD, Philippe Quittet, MD, Franck Morschhauser, MD, Vincent Ribrag, MD, Veronique Edeline, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 132.

https://doi.org/10.1182/blood-2019-123925

Published: 2019

Journal Articles

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Autumn Diadamo, BS, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5174.

https://doi.org/10.1182/blood-2019-127277

Published: 2019

Journal Articles

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Blood (2019) 134 (Supplement_1): 353.

https://doi.org/10.1182/blood-2019-129835

Published: 2019

Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD

Blood (2019) 134 (Supplement_1): 4093.

https://doi.org/10.1182/blood-2019-126369

Published: 2019

Journal Articles

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Liora M Schultz, MD, Shabnum Patel, PhD, Sneha Ramakrishna, MD, Alice Bertaina, MD PhD, Neehar Bhatia, Jean Oak, MD PhD, Robbie G. Majzner, MD, Christina Baggott, RN, PhD, Kara L. Davis, DO, Crystal L. Mackall, MD, Steven A Feldman, PhD

Blood (2019) 134 (Supplement_1): 4471.

https://doi.org/10.1182/blood-2019-129436

Published: 2019

NARROW

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

A Novel 10-Fluorochrome Multiparameter Flow Cytometry (MFC) Panel for Precise Plasma Cell (PC) and MRD Assessment in Clinical Routine of Multiple Myeloma (MM) Patients and throughout the Disease Course

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Successful Treatment of Refractory Acute Lymphoblastic Leukemia with Tisagenlecleucel in the Setting of Life-Threatening Infection

Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Influence of CD27 - CD28 - T-Cells on the Therapeutic Outcome in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma after CART-Infusion

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis

A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia

Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only